LASIK Eye Surgery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The lASIK eye surgery devices market size is expected to increase from USD 2.42 billion in 2025 to USD 2.55 billion in 2026 and reach USD 3.34 billion by 2031, growing at a CAGR of 5.52% over 2026-2031. This report is Segmented by Product Type (Femtosecond Lasers, Excimer Lasers, Other Devices), Technology (Wavefront-Guided, Wavefront-Optimized, Topography-Guided, Other), Application (Myopia, Hyperopia, Astigmatism, Presbyopia), End User (Eye Clinics, Hospitals, Ambulatory Surgical Centers, Others), and Geography (North America, Europe, and More). Market Forecasts are in Terms of Value (USD).

Global LASIK Eye Surgery Devices Market Trends and Insights

Rising Myopia and Astigmatism Burden

The LASIK eye surgery devices market is drawing long-term support from the steady rise in myopia and related refractive conditions across children, adolescents, and young adults. A 2025 meta-analysis covering 276 studies and more than 5.4 million participants found that global myopia prevalence among children and adolescents rose from 24.32% in 1990 to 35.81% in 2023. The same body of evidence points to a much larger future treatment pool as these patients move into the age band where refractive surgery becomes clinically suitable. East Asia remains the most intense pressure point, with WHO regional data showing adolescent myopia rates approaching 80% in some China and Singapore cohorts. Astigmatism often appears alongside myopia, which means rising case volumes are not limited to simple spherical correction and increasingly favor platforms with stronger cylinder management. That pattern is helping the LASIK eye surgery devices market move toward systems that can treat more complex visual profiles rather than only high-volume routine cases.

Shift From Blade-Based to All-Laser LASIK

The LASIK eye surgery devices market is also being lifted by the continued move away from blade-based procedures and toward all-laser treatment workflows. In March 2025, the US FDA approved the WaveLight EX500 Laser System with INNOVEYES Sightmap, the first ray-tracing personalized LASIK system to receive that clearance. Alcon later reported real-world results from 200 patients and 400 eyes treated with wavelight plus, with 100% of myopic eyes reaching 20/20 uncorrected distance visual acuity at 3 months and 89% reaching 20/16. A 2025 study in BMC Ophthalmology also found that ray-tracing-guided LASIK reduced overcorrection ratios relative to standard approaches. These results are pushing patient expectations upward at premium centers and raising pressure on older installations that cannot deliver the same planning depth or treatment precision. The LASIK eye surgery devices market is therefore seeing replacement demand shaped as much by outcome expectations and software capability as by hardware age.

High Upfront Device and Maintenance Cost

High capital cost remains 1 of the clearest adoption limits for the LASIK eye surgery devices market, especially outside major urban care clusters. Premium femtosecond and excimer systems usually require initial spending from USD 300,000 to more than USD 700,000 per unit, with annual service contracts of USD 40,000 to USD 80,000. That cost base is difficult for lower-volume centers to absorb and often pushes purchasing decisions toward delayed upgrades or second-hand systems. The burden is not limited to initial purchase price because excimer systems also depend on specialty gases and optics support that add recurring operating expense. This makes utilization rates critical, since centers with weaker procedure density have less room to recover capital and service costs over time. The result is a slower placement pace for new platforms in cost-sensitive regions even when clinical demand for refractive correction is rising.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of High-Volume Refractive Surgery Centers
• Higher Upgrade Cycles for Wavefront and Topography-Guided Platforms
• Limited Insurance Coverage for Elective Vision Correction

Segment Analysis

Femtosecond lasers held 42.31% of the LASIK eye surgery devices market share in 2025, making them the largest product segment in the LASIK eye surgery devices market. Their lead reflects the established role of bladeless flap creation in premium refractive workflows and the strong preference for reproducible incision geometry. Surgeons also value the ability to control flap thickness more precisely and reduce epithelial complications compared with mechanical systems. A Harvard review traced the evolution of femtosecond lasers from LASIK-specific tools into broader corneal surgery platforms, which strengthens utilization economics for each installed system. That broader use case supports higher capital justification and helps maintain premium pricing even when procedure competition intensifies. The LASIK eye surgery devices industry therefore continues to treat femtosecond placement as both a refractive asset and a wider ophthalmic capability investment.

Excimer lasers are the fastest-growing product segment, with the LASIK eye surgery devices market size for this segment projected to expand at a 7.38% CAGR from 2026 to 2031. Recent regulatory clearances widened their addressable use and improved the case for dual-platform adoption. Bausch + Lomb received FDA approval for the TENEO Excimer Laser Platform for myopia and myopic astigmatism LASIK vision correction surgery in January 2024. The FDA also lists the MEL 90 among approved lasers for LASIK, reinforcing the broader indication expansion underway in the category. As these approvals expand treatment flexibility, centers that once relied on limited refractive setups are moving toward combined femtosecond and excimer ownership. That transition supports incremental excimer demand even when overall procedure growth is steady rather than abrupt.

Wavefront-guided LASIK accounted for 43.24% of revenue in 2025, giving it the leading technology position within the LASIK eye surgery devices market. Its large installed base and long clinical track record continue to support demand at high-volume refractive centers. A 2025 prospective contralateral-eye study reported that wavefront-guided LASIK delivered a statistically significantly higher rate of 20/12.5 visual outcomes than topography-guided LASIK at 12 months. That supports its role in standard myopia cases where corneal irregularity is limited and precision consistency matters most. Wavefront-optimized systems also retain an efficiency advantage in busy centers that value shorter treatment planning and throughput discipline. The LASIK eye surgery devices industry still depends on this installed base for a large part of current technology revenue.

Topography-guided LASIK is the fastest-growing technology segment, with a projected CAGR of 6.52% from 2026 to 2031 in the LASIK eye surgery devices market. The segment is benefiting from stronger surgeon comfort, more visible patient-facing differentiation, and better fit in irregular or complex astigmatic cases. Alcon’s Contoura Topo-G pivotal study showed 93% of eyes reaching 20/20 uncorrected distance visual acuity or better and 32% reaching 20/12.5 or better. A 2024 expanded cohort study found that wavefront-guided and topography-guided platforms both achieved close to 90% of eyes at 20/20 or better, showing that multiple technology paths can remain clinically credible. The next layer of competition is already emerging through ray-tracing systems, which connect diagnostic depth more tightly to ablation planning. That means technology competition in the LASIK eye surgery devices market is shifting from simple treatment categories into outcome-specific workflow design.

Complete Report Scope:

• By Product Type
  • Femtosecond Lasers
  • Excimer Lasers
  • Other LASIK Devices
• By Technology
  • Wavefront-Guided LASIK
  • Wavefront-Optimized LASIK
  • Topography-Guided LASIK
  • Other Technologies
• By Application
  • Myopia
  • Hyperopia
  • Astigmatism
  • Presbyopia
• By End User
  • Eye Clinics
  • Hospitals
  • Ambulatory Surgical Centers
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 45.52% of the LASIK eye surgery devices market share in 2025, which made it the largest regional market. The region combines high procedure awareness, dense refractive surgery infrastructure, and an active approval environment for new devices and treatment upgrades. Between January 2024 and March 2025, major platforms such as TENEO and the personalized WaveLight EX500 with INNOVEYES Sightmap received U.S. regulatory clearance or approval, reinforcing the pace of premium system renewal. The LASIK eye surgery devices market in the region also benefits from a large base of outpatient eye care providers that can absorb high-end capital equipment. South America remains smaller, with Brazil and Argentina as the most active procedure centers in the region, supported by private eye care concentration and medical travel patterns.

Europe remained the second-largest regional block in the LASIK eye surgery devices market, supported by mature refractive surgery activity in Germany, the United Kingdom, and Spain. Germany continues to support demand for advanced capability platforms through specialty clinics and academic refractive centers. The United Kingdom also maintains stable private-pay LASIK demand outside public reimbursement, which supports consistent procedure volumes. Across the region, stricter EU Medical Device Regulation requirements are extending commercialization timelines for new ablation profiles and software updates, which favors larger companies with stronger regulatory infrastructure.

Asia-Pacific is the fastest-growing regional segment, with the LASIK eye surgery devices market size in the region projected to advance at 7.45% CAGR from 2026 to 2031. China and India remain the main growth engines because both markets combine expanding private eye care capacity with a large future treatment pool. WHO Western Pacific data show very high adolescent myopia prevalence in several East Asian settings, which keeps the long-term patient pipeline structurally strong. South Korea also supports regional growth through a strong domestic refractive surgery base and cost-competitive appeal for cross-border patients. The Middle East and Africa continue to develop from a smaller base, led by Saudi Arabia and the UAE where medical tourism, higher disposable incomes, and specialist care investment are supporting procedure demand. Across emerging regions, growth remains real, but it is moderated by capital cost, regulatory entry requirements, and the need for trained refractive surgery teams.

List of Companies Covered in this Report:

• Alcon
• Appasamy Associates Private Limited
• Bausch + Lomb Incorporated
• BVI Medical
• Carl Zeiss
• iVIS Technologies S.r.l.
• Johnson & Johnson Vision Care, Inc.
• LaserSight Technologies, Inc.
• LensAR, Inc.
• Lumenis
• Moria S.A.
• Nidek
• Optikon 2000 S.p.A.
• SCHWIND eye-tech-solutions GmbH & Co. KG
• Topcon
• Trivitron Healthcare
• Ziemer Group

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support